Table 4.

Additional outcomes for comparison of intramuscular botulinum toxin to placebo or to triamcinolone in patients with shoulder spasticity.

OutcomeNo. StudiesNo. PatientsMean difference or Risk Ratio* (95% CI)
Intramuscular botulinum toxin compared to placebo: outcomes at 4–6 and 12–24 weeks
  Pain (0–10 cm VAS or verbal rating scale)
    At 4–6 wks486−1.12 (−2.89, 0.66)
    At 12–24 wks366−1.22 (−2.37, −0.07)**
  Spasticity on modified Ashworth Scale (0–5; higher = worse)
    At 4–6 wks245−0.62 (−1.40, 0.17)
    At 12–24 wks245−0.13 (−0.65, 0.38)
  Passive shoulder flexion (0–180; higher = better function)1
    At 4–6 wks1293.00 (−15.54, 21.54)
    At 12–24 wks1291.00 (−17.87, 19.87)
  Passive shoulder abduction (0–180; higher = better function)
    At 4–6 wks3658.49 (−2.40, 19.39)
    At 12–24 wks24517.72 (−9.61, 45.04)
  Shoulder external rotation (0–180; higher = better function)
    At 4–6 wks3709.84 (0.20, 19.49)**
    At 12–24 wks25011.86 (−0.61, 24.33)
  No. adverse events3651.46 (0.64, 3.36)
    At 4–6 wks1203.00 (0.37, 24.17)
    At 12–24 wks2450.84 (0.10, 7.10)
Intramuscular botulinum toxin compared to triamcinolone: outcomes at 12 weeks
  Change in pain on 0–10 numeric rating scale (higher = more pain)1291.70 (−0.08, 3.48)
  Change in physician global rating scale (0–4; 4 = maximum improvement)1290.00 (−0.72, 0.72)
  Change in passive shoulder flexion (0–180; higher = better function)1298.30 (−4.06, 20.66)
  Change in passive shoulder abduction (0–180; higher = better function)1295.60 (−6.05, 17.25)
  Change in passive shoulder external rotation (0–90; higher = better)1297.90 (−5.30, 21.10)
  Change in passive shoulder internal rotation (0–90; higher = better)1299.30 (−0.36, 18.96)
  Change in spasticity on modified Ashworth Scale (0–5; higher = worse)129−0.20 (−1.00, 0.60)
  • * All numbers are mean differences except number of adverse events for which risk ratio is presented.

  • ** Significant with p < 0.03 for all. VAS: visual analog scale.